ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2004
Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra.
Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Concordance analysis of microarray studies identifies representative gene expression changes in Parkinson's disease: a comparison of 33 human and animal studies.BMC neurology · 2017Pooled it
- Initial Molecular Mechanisms of the Pathogenesis of Parkinson's Disease in a Mouse Neurotoxic Model of the Earliest Preclinical Stage of This Disease.International journal of molecular sciences · 2024Article
- Cortistatin as a Novel Multimodal Therapy for the Treatment of Parkinson's Disease.International journal of molecular sciences · 2024Article
- In vivo overexpression of synaptogyrin-3 promotes striatal synaptic dopamine uptake in LRRK2Brain and behavior · 2023Article
- Transcriptional Regulation of the Synaptic Vesicle Protein Synaptogyrin-3 (International journal of molecular sciences · 2022Article
- Article
- Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction.PLoS genetics · 2020Article
- Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model.Journal of neurochemistry · 2016Article
- Gene expression of proteins of the vesicle cycle in the striatum and motor cortex under functional failure of nigrostriatal system.Doklady. Biochemistry and biophysics · 2016Article
- Gene expression of proteins of the vesicle cycle in dopaminergic neurons in modeling of Parkinson's disease.Doklady. Biochemistry and biophysics · 2016Article
- Validity of the MPTP-Treated Mouse as a Model for Parkinson's Disease.Molecular neurobiology · 2016Article
- Gene dysregulation is restored in the Parkinson's disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm).Scientific reports · 2016Article
- Advancing Risk Assessment through the Application of Systems Toxicology.Toxicological research · 2016Article
- 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.Neuroscience · 2015Article
- MPTP's pathway of toxicity indicates central role of transcription factor SP1.Archives of toxicology · 2015Article
- Developing tools for defining and establishing pathways of toxicity.Archives of toxicology · 2015Article
- From smoking guns to footprints: mining for critical events of toxicity pathways in transcriptome data.Archives of toxicology · 2015Article
- Expression analysis of the long non-coding RNA antisense to Uchl1 (AS Uchl1) during dopaminergic cells' differentiation in vitro and in neurochemical models of Parkinson's disease.Frontiers in cellular neuroscience · 2015Article
- Article
- α-Synuclein overexpression represses 14-3-3θ transcription.Journal of molecular neuroscience : MN · 2013Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Parkinson's disease pathogenesis proceeds through several phases, culminating in the loss of dopaminergic neurons of the substantia nigra (SN). Although the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of oxidative SN injury is frequently used to study degeneration of dopaminergic neurons in mice and non-human primates, an understanding of the temporal sequence of molecular events from inhibition of mitochondrial complex 1 to neuronal cell death is limited. Here, microarray analysis and integrative data mining were used to uncover pathways implicated in the progression of changes in dopaminergic neurons after MPTP administration. This approach enabled the identification of small, yet consistently significant, changes in gene expression within the SN of MPTP-treated animals. Such an analysis disclosed dysregulation of genes in three main areas related to neuronal function: cytoskeletal stability and maintenance, synaptic integrity, and cell cycle and apoptosis. The discovery and validation of these alterations provide molecular evidence for an evolving cascade of injury, dysfunction, and cell death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.